About The Epsilon Group

Since its founding in 2000, The Epsilon Group has been committed to enabling personalized solutions for the management and treatment of diseases through post marketing and hospital-based research. This is accomplished with two primary solutions: the Type 1 Diabetes Metabolic Simulator (T1DMS) and Diabetes Mellitus Metabolic Simulator for Research (DMMS.R).


Over the last seven years, the Distributed Version of the T1DMS software has been used by at least 14 academic research groups and two commercial research groups with ever-growing industry interest. Additionally, TEG has provided T1DMS simulation services for three companies, two of which submitted IDEs and received FDA approvals, with simulation study results delivered in months as opposed to years of pre-clinical trials. In partnership with several commercial entities, TEG performed simulation services and data analyses that are leading to improved accuracy and better performance by medical devices. Such devices are currently or soon-to-be on the market. TEG continues to foster solutions for diabetes care with in silico modeling and simulation to test and improve new technologies in accordance with FDA regulatory requirements, as well as with online services for R&D and education in the industry.


The Diabetes Mellitus Metabolic Simulator for Research (DMMS.R) is a computer application designed for conducting clinical studies in virtual subjects with T1, T2 or Pre-Diabetes. It provides a unique in silico environment for testing diabetes treatment and monitoring interventions, and is ideal for modeling new devices or examining treatment protocols and dosing algorithms. The user can design device models, implement test protocols that rigorously examine the performance of a control algorithm, evaluate the subject response to drug treatments, and assess the performance of sensors and pumps in the in silico environment before clinical testing.

Modeling and simulation of diabetes drugs and treatments early in development can help the user make informed decisions regarding:

  • optimal dosing regimens over the full variability of people with the disease
  • safety under extreme lifestyle management patterns
  • further development to reduce costly failures
Scroll to Top